Compare AbCellera Biologics Inc (ABCL) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Starbucks Corp — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Starbucks Corp trades at $103.22 (market cap $118.08B). The key difference: Starbucks Corp is far larger — about 50.2× AbCellera Biologics Inc's market cap, and Starbucks Corp pays a 2.39% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SBUX | |
|---|---|---|
Market Cap | $2.35B | $118.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $106.82 |
52-Week Low | $2.78 | $78.46 |
Enterprise Value | $1.99B | $140.78B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Starbucks (SBUX) trades at $103.61, down 0.62% with a bullish technical signal despite recent price weakness. The company shows mixed fundamentals with declining net income margins (3.89% in 2025) but stable revenue growth. Recent earnings beat expectations in Q1 2026 after two consecutive misses. Analyst consensus remains positive with a $107.67 price target, though technical indicators show neutral oscillators and key resistance at $104.
SBUX faces margin pressure but benefits from strong brand loyalty and store traffic initiatives. Investment opportunity lies in international expansion and operational improvements, while risks include competitive pressures and cost inflation. The stock offers moderate upside potential with balanced analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
